Figure 4.
Schematic illustrating the role of Gevokizumab-armed platelet microparticles as cardiac detoxification and repair agents. By taking advantage of the natural infarct-homing abilities of platelet membranes, a platelet-mimicking system that uses anti-IL-1β-neutralizing antibodies was developed in this study. This system functions as an IL-1β decoy that reduces the local inflammatory response in the injured heart in a targeted way. Reproduced with permission [159].
